Business Context and Reporting Period
This Form 6-K filing by CollPlant Biotechnologies Ltd. covers the month of April 2026, with the report dated April 13, 2026. The company is a foreign private issuer based in Rehovot, Israel, focusing on biotechnology solutions.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a material corporate event rather than periodic financial results.
Material Changes
- Termination of Development Agreement: On April 9, 2026, Allergan Industrie SAS (an AbbVie company) notified CollPlant of its decision to terminate a development agreement originally signed in February 2021.
- Effective Date: The termination will take effect on June 8, 2026, following a 60-day advance notice period.
- Project Scope: The terminated agreement involved the development of a dermal and soft tissue filler product for the medical aesthetics market using CollPlant's rhCollagen technology over the prior five years.
Outlook, Risks, and Management Commentary
On April 13, 2026, the Company issued a press release titled "CollPlant Issues Letter to Shareholders," which is incorporated by reference as Exhibit 99.1. The termination of the AbbVie agreement represents a significant change in the company's partnership landscape and may impact future revenue streams related to the rhCollagen technology in the medical aesthetics sector. The filing does not provide specific forward-looking guidance or quantitative risk assessments beyond the notification of the contract termination.
Investor Verification Checklist
- Review the attached "Letter to Shareholders" (Exhibit 99.1) for management's detailed response to the termination.
- Assess the financial impact of losing the AbbVie partnership on future cash flow projections.
- Verify if the termination triggers any contractual penalties or requires the return of previously received funding.
- Monitor subsequent filings for updates on the status of the rhCollagen technology and potential new commercialization partners.